RxDoctor Payments Data

Juris Treibergs, MD

Psychiatry · Plymouth, MANPI 1790760098

Payments from drug & device makers

$27,851in general payments, 2019–2025

Across 185 payments — averaging $150.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$26K
  • AbbVie$294
  • Teva Pharmaceuticals USA, Inc.$229
  • Otsuka America Pharmaceutical, Inc.$220
  • Lundbeck LLC$164
  • Alkermes, Inc.$129
  • plus $564 from 10 others

What the payments were for

  • Speaking & faculty fees$22,14580%
  • Travel & lodging$1,9317%
  • Food & beverage$3,56113%
  • Education$2141%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,851 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$83,896
Medicare patients
191
Services billed
781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole25$44,075
VraylarCariprazine Hcl24$43,854
VyvanseLisdexamfetamine Dimesylate77$37,880
Abilify MaintenaAripiprazole12$32,120
Aripiprazole106$13,674
Lurasidone Hcl29$12,619
TrintellixVortioxetine Hydrobromide12$10,668
Methylphenidate ErMethylphenidate Hcl42$7,110
Lisdexamfetamine Dimesylate28$4,919
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine42$4,631
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine180$4,285
Duloxetine Hcl156$4,227
Clonazepam458$3,401
Quetiapine Fumarate111$3,308
Alprazolam373$3,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$220$76,19537 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$113$48,54889 claims
AbbVieVraylar$294$43,85424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in Plymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →